Bogdanowicz E, Kalinowski A, Swiecicki L
II Kliniki Psychiatrycznej Instytutu Psychiatrii i Neurologii.
Psychiatr Pol. 1991 May-Aug;25(3-4):19-24.
28 patients aged from 31 to 69 years with endogenous depression were studied. All cases were drug-resistant i.e. they did not improve after a treatment with tricyclic antidepressants and in four cases also after electroconvulsive therapy. The group were managed with intravenous infusions of clomipramine or maprotiline followed by oral administration of the drug. Clomipramine was given i.v. at doses 75-300 mg daily for 7 to 16 days and maprotiline at 75-200 mg daily for 6 to 20 days. Remission of depressive symptoms was observed in 43% of cases and the first signs of improvement were observed on tenth day of the treatment. Tolerance to both drugs given parenterally in majority of cases was satisfactory. Half of the group did not show any untoward events. The rest of the group displayed local tissue reactions, both increased and decreased blood pressure, weakness, drowsiness, anxiety, vertigo, hyperpyretic reactions. Four patients had the treatment discontinued because of local tissue reactions or increased blood pressure or hyperpyretic reactions.
对28名年龄在31至69岁之间的内因性抑郁症患者进行了研究。所有病例均耐药,即在用三环类抗抑郁药治疗后病情未改善,其中4例在接受电休克治疗后也无改善。该组患者先静脉输注氯米帕明或马普替林,随后口服给药。氯米帕明静脉注射剂量为每日75 - 300毫克,持续7至16天,马普替林每日75 - 200毫克,持续6至20天。43%的病例观察到抑郁症状缓解,治疗第10天观察到首次改善迹象。在大多数情况下,对两种胃肠外给药的药物耐受性良好。该组一半患者未出现任何不良事件。其余患者出现局部组织反应、血压升高和降低、虚弱、嗜睡、焦虑、眩晕、高热反应。4名患者因局部组织反应、血压升高或高热反应而停止治疗。